URINARY BLADDER NEOPLASMS
Clinical trials for URINARY BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new URINARY BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for URINARY BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental bladder cancer drug shows promise but trial halted early
Disease control TerminatedThis study tested an experimental drug called enfortumab vedotin, alone or with other cancer drugs, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and control the disease. The trial included 348 participants but was te…
Matched conditions: URINARY BLADDER NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New bladder cancer drug delivered directly into bladder shows early promise
Disease control TerminatedThis early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…
Matched conditions: URINARY BLADDER NEOPLASMS
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Bladder cancer drug combo trial halted early – what does it mean?
Disease control TerminatedThis phase 3 trial tested whether adding nivolumab (an immunotherapy drug) to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the study was stopped early, so we don't have clear results on wheth…
Matched conditions: URINARY BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC